Journal
NATURE REVIEWS DRUG DISCOVERY
Volume 10, Issue 11, Pages 835-852Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/nrd3578
Keywords
-
Funding
- International Atherosclerosis Society
- National Heart, Lung, and Blood Institute (NHLBI)
- US National Institutes of Health (NIH) [HHSN268201000045C]
- NIH [R01 EB009638, R01 CA155432]
Ask authors/readers for more resources
The use of nanotechnology for medical purposes - nanomedicine - has grown exponentially over the past few decades. This is exemplified by the US Food and Drug Administration's approval of several nanotherapies for various conditions, as well as the funding of nanomedical programmes worldwide. Although originally the domain of anticancer therapy, recent advances have illustrated the considerable potential of nanomedicine in the diagnosis and treatment of atherosclerosis. This Review elaborates on nanoparticle-targeting concepts in atherosclerotic disease, provides an overview of the use of nanomedicine in atherosclerosis, and discusses potential future applications and clinical benefits.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available